FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation–Positive Low-Grade Glioma
Authors:
- Michael I. BarbatoMBMichael I. Barbato
- Jeannette NashedJNJeannette Nashed
- Diana BradfordDBDiana Bradford
- Yi RenYRYi Ren
- Sachia KhasarSKSachia Khasar
- Claudia P. MillerCMClaudia P. Miller
- Banu S. ZolnikBZBanu S. Zolnik
- Hong ZhaoHZHong Zhao
- Yangbing LiYLYangbing Li
- Youwei BiYBYouwei Bi
- Stacy S. ShordSSStacy S. Shord
- Anup K. AmatyaAAAnup K. Amatya
- 23 August 2023
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (2) , 263-268
Abstract
On March 16, 2023, the FDA approved dabrafenib in combination with trametinib (Tafinlar, Mekinist; Novartis Pharmaceuticals Corporation) for the treatment of pediatric patients with low-grade glioma (LGG) with a BRAFV600E mutation who require systemic therapy. FDA also approved oral formulations of both drugs suitable for patients who cannot swallow pills. This approval was based on the LGG cohort from study CDRB436G2201 (NCT02684058), a multicenter, open-label trial in which pediatric patients with LGG with a BRAFV600E mutation were randomly assigned 2:1 to dabrafenib plus trametinib (D+T) or carboplatin plus vincristine (C+V). The overall response rate (ORR) by independent review based on Response Assessment in Neuro-oncology LGG (2017) criteria was assessed in 110 patients randomly assigned to D+T (n = 73) or C+V (n = 37). ORR was 47% [95% confidence interval (CI), 35–59] in the D+T arm and 11% (95% CI, 3.0–25) in the C+V arm. Duration of response (DOR) was 23.7 months (95% CI, 14.5–NE) in the D+T arm and not estimable (95% CI, 6.6– NE) in the C+V arm. Progression-free survival (PFS) was 20.1 months (95% CI: 12.8, NE) and 7.4 months (95% CI, 3.6– 11.8) [HR, 0.31 (95% CI, 0.17–0.55); P < 0.001] in the D+T and C+V arms, respectively. The most common (>20%) adverse reactions were pyrexia, rash, headache, vomiting, musculoskeletal pain, fatigue, diarrhea, dry skin, nausea, hemorrhage, abdominal pain, and dermatitis acneiform. This represents the first FDA approval of a systemic therapy for the first-line treatment of pediatric patients with LGG with a BRAFV600E mutation.Keywords
Funding Information
- U.S. Food and Drug Administration
This publication has 15 references indexed in Scilit:
- A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – A final reportEuropean Journal of Cancer, 2017
- Response Assessment in Neuro-Oncology Clinical TrialsJournal of Clinical Oncology, 2017
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in MelanomaNew England Journal of Medicine, 2014
- Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic TargetingFrontiers in Oncology, 2014
- The clinical development of MEK inhibitorsNature Reviews Clinical Oncology, 2014
- Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012
- Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomasThe Lancet Oncology, 2011
- Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Cancer Survivor StudyJNCI: Journal of the National Cancer Institute, 2009
- MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomasCell Cycle, 2009
- Mutations of the BRAF gene in human cancerNature, 2002